Has anyone with Synovial Sarcoma been involved with a clinical trial on M8891?
For anybody wondering about this trial, its description is here:
This is a phase 1 trial open to solid tumors with few locations, none of which are well-known sarcoma centers. The chance they were willing or managed to recruit synovial sarcoma patients is very small.
The drug is interesting. It is a methionine aminopeptidase-2 inhibitor, which apparently targets angiogenesis. This type of inhibitor hasn’t been studied in synovial sarcoma as far as I know. It’s really a shot in the dark…